• br Soluble guanylyl cyclase nitric

  2021-10-11

  

  Soluble guanylyl cyclase, nitric oxide and nitric oxide synthase The primary and best-studied endogenous activator of soluble guanylyl cyclase (sGC) is nitric oxide (NO), which was originally describe as endothelium-derived relaxing factor for its potent ability to relax blood vessels in response

• To determine the functional consequences of HIV gp

  2021-10-11

  

  To determine the functional consequences of HIV gp120 binding to vaginal epithelial cells, an annotation clustering of the differentially expressed genes was performed. The top enriched biological processes included an inflammatory immune response, defense response and the pathways included the SODD

• GPR A a G protein coupled receptor located

  2021-10-11

  

  GPR109A, a G-protein-coupled receptor located mainly on adipocyte cell membranes, has been identified as the molecular target for nicotinic pkc inhibitors [[5], [6], [7]] and mediator of NEFA reduction [5]. As a mechanism of NEFA-lowering, it is recognized that activation of GPR109A leads to Gi-med

• Taken together specific antibodies and SR SIM used

  2021-10-11

  

  Taken together, specific p2y receptor and SR-SIM used in the study helped uniquely visualize the distribution of lymphocytes and macrophages with their molecular expression in human cochleae. Using SR-SIM, we verified that resident IBA1-positive macrophages are widely distributed in human cochlea (

• Crystal structures from soluble E constructs Khan et

  2021-10-11

  

  Crystal structures from soluble E2 constructs (Khan et al., 2014; Kong et al., 2013) have revealed globular protein with no regular structure in spite of having eight disulphide bonds (Kong et al., 2013). Although 62% of the protein exists in loops or disordered structures, overall it was well-defin

• Entry into CNS is tightly regulated by highly dynamic

  2021-10-11

  

  Entry into CNS is tightly regulated by highly dynamic barriers, namely, the BBB, the blood-CSF barrier, and the arachnoid epithelium (Abbott et al., 2010; Yasuda et al., 2013). Similar barriers also exist within the CNS including the ependymal barrier as well as the cellular membrane barriers of the

• Here we studied GLUT targeted

  2021-10-11

  

  Here, we studied GLUT1-targeted nanomedicines as a new strategy directed to overcome vascular barrier, enhancing delivery and efficacy in solid tumors. These nanomedicines were prepared by controlled installation of glucose on polymeric micelles incorporating the antitumor agent cisplatin, which is

• Since the isoflavone emerged as

  2021-10-11

  

  Since the isoflavone emerged as privileged scaffold in Hh inhibition, based on molecular modeling predictions and prior studies [17,22], here we designed a number of isoflavones able to interact preferentially with the Smo receptor or the Gli protein. Molecules were synthesized by means of a novel s

• Introduction galactosidase d galactoside galactohydrolase

  2021-10-11

  

  Introduction β-galactosidase (β-d-galactoside galactohydrolase or lactase; EC 3.2.1.23) is an important type of glycoside hydrolase that can catalyze the conversion of lactose to 550 24 and galactose. Furthermore, it can also catalyze transglycosylation reactions, which are usually used for the syn

• In addition to SAHA SBHA also showed a strong rescue

  2021-10-09

  

  In addition to SAHA, SBHA also showed a strong rescue effect. SAHA is a general inhibitor of HDAC function (Finnin et al., 1999, Kim and Bae, 2011), while SBHA is more specific, and has been shown to inhibit HDAC1 and HDAC3 (Richon et al., 1998). The relative level of suppression was similar in Kis

• br Acknowledgments br Introduction Histone deacetylases HDAC

  2021-10-09

  

  Acknowledgments Introduction Histone deacetylases (HDACs) related to tumor suppressor genes have become promising targets for the treatment of cancer [1,2]. Under the normal physiological conditions, Histone acetyltransferases (HATs) and histone deacetylases (HDACs) together regulate the acety

• br Background To treat chronic

  2021-10-09

  

  Background To treat chronic HCV genotype (GT) 1-infected patients, telaprevir (TLP) or boceprevir (BOC), first generation protease inhibitors (PIs), were used in combination with pegylated-interferon (PEG-IFN) and ribavirin (RBV) triple therapy [1], [2]. The main weaknesses of the first-generatio

• Cordycepin There are five main research findings regarding p

  2021-10-09

  

  There are five main research findings regarding possible mechanisms of low-level HBsAg expression: Most of these findings are related to the use of antiviral therapy, which results in pre-S/S gene mutations, the development of occult hepatitis, the use of immunosuppressants or S gene methylation, b

• For the SAR study human

  2021-10-09

  

  For the SAR study, human haspin kinase inhibitory activity of the various compounds was evaluated using the same assay utilized for the HTS, except in the presence of varying test compound concentrations. DYRK2 kinase inhibitory activity was measured by P-incorporation into Woodtide peptide substrat

• In the present study we

  2021-10-09

  

  In the present study, we focused on a role of the C-terminal segment in GCAP2 using two chimeric proteins, in which the C-terminal segment of GCAP2 was either replaced by the corresponding sequence of recoverin (chimera GR) or transferred into recoverin (chimera RG). We have monitored Ca-dependent c

15211 records 534/1015 page Previous Next First page 上5页 531532533534535 下5页 Last page